On August 14, 2026, Dare Bioscience entered into a securities purchase agreement to sell 4,379,581 shares of common stock and pre-funded warrants at $1.37 per share in a registered direct offering. The company raised approximately $6.0 million in gross proceeds before expenses. Concurrently, the firm issued Series A and Series B warrants exercisable for up to 4,379,581 shares each at an exercise price of $1.37 per share. Proceeds will support working capital, general corporate purposes, and its 503B compounding and consumer health strategies. The closing is expected on August 17, 2026. Dare Bioscience operates in the biotechnology industry, focusing on women's health solutions.

Daré Bioscience reported financial results for the quarter ended June 30, 2026. The company generated total revenue of $0.2 million, driven by research and development services from Gates Foundation agreements, compared to negative revenue in the prior year period. Operating expenses were approximately $2.8 million, resulting in a net loss of $2.98 million. As of June 30, 2026, Daré held approximately $12.6 million in cash and cash equivalents with a working capital deficit of $0.2 million. Commercially, the company launched Flora Sync LF5 as its first direct-to-consumer product and is preparing for prescription dispensing of DARE to PLAY Sildenafil Cream in Q3 2026. The pipeline advanced with positive interim Phase 3 results for Ovaprene and initiation of a Phase 2 study for DARE-HPV, supported by $2.0 million in total NIH funding. Daré Bioscience is a biotech company focused on developing women's health products.

Daré Bioscience, Inc. furnished a corporate presentation dated July 24, 2026, for use in meetings with securities market participants. The company is a clinical-stage biopharmaceutical company focused on women's health. }{

Dare Biosciences, Inc. was notified by Nasdaq Listing Qualifications Staff that its common stock is subject to delisting because the company's stockholders' equity was less than $2.5 million as of the period ended March 31, 2026, and it failed to meet alternative listing requirements. The company intends to request a hearing before a Nasdaq Hearing Panel to stay the suspension and delisting. Dare Biosciences, Inc. is a biotechnology company focused on developing and commercializing women's health products.